1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437

Awaiting development [GID-TA11563] Expected publication date: TBC

  • Project information
  • Project documents

33922-Brentuximab-Vedotin-Chemotherapy-for-Classical-Hodgkin-Lymphoma-V1.0-JAN2024-NON-CONF.pdf (nihr.ac.uk)